Chronic myeloid leukemia - Some topical issues

Leukemia

Volumn 21, Issue 7, 2007, Pages 1347-1352

  Mughal, T ^a   Cortes, J ^b   Cross, N C P ^c   Donato, N ^d   Hantschel, O ^e   Jabbour, E ^b   Kantarjian, H ^b   Melo, J V ^f   Skorski, T ^g   Silver, R T ^h   Goldman, J M ^f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; BCR ABL PROTEIN; BOSUTINIB; CD19 ANTIGEN; CD34 ANTIGEN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DNA DIRECTED DNA POLYMERASE BETA; FINGOLIMOD; GNF 2; HEMATOPOIETIC CELL KINASE; IMATINIB; INNO 406; INTERLEUKIN 3; INTERLEUKIN 7; IPI 504; NILOTINIB; NS 187; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE FYN; PROTEIN KINASE LYN; PROTEIN P190; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SGX 70393; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA STRAND BREAKAGE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TREATMENT FAILURE; EDITORIAL; ENZYME INHIBITION; GENE DELETION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; GENOMIC INSTABILITY; HEART FAILURE; HUMAN; LEUKEMIA REMISSION; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; NONHUMAN; OPTIMAL DRUG DOSE; OXIDATIVE STRESS; PLEURA EFFUSION; POINT MUTATION; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; RECOMMENDED DRUG DOSE; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 34250730732     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404733     Document Type: Editorial

References (44)

1. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104: 3746-3753.
2. Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A et al. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle 2006; 5: 994-1000.
3. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowick MO et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8: 795-806.
4. Gaymes TJ, Mufti GJ, Rassool FV. Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res 2002; 62: 2791-2797.
5. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319-327.
6. Penserga ET, Skorski T. Fusion tyrosine kinases: A result and cause of genomic instability. Oncogene 2006; 26: 11-20.
7. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004; 5: 33-44.
8. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-183.
9. Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong A, Goldman JM et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005; 65: 8912-8919.
10. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlington DM. Lyn tyrosine kinase: Accentuating the positive and the negative. Immunity 2005; 22: 9-18.
11. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996; 56: 3589-3596.
12. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 136: 453-461.
13. Meyn MA, Wilson MB, Abdi FA, Fahey N, Schiavone AP, Wu J et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006; 281: 30907-30916.
14. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004; 10: 1187-1189.
15. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-698.
16. Neviani P, Santhanam R, Trotta R, Notari M, Blazer BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355-368.
17. Kahan BD. FTY720: From bench to bedside. Transplant Proc 2004; 36: 531S-543S.
18. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer 2006; 95: 775-781.
19. Brinkmann V. FTY720: Mechanism of action and potential benefit in organ transplantation. Yonsei Med J 2004; 45: 991-997.
20. Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 2005; 65: 7478-7484.
21. Druker BJ, Guilhot F, O'Brien SG, Gathamnn I, Kantarjian H, Gattermann N et al. Five-year follow-up of imatinib therapy for newly diagnosed chronic myeloid leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med 2006; 355: 2408-2417.
22. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA et al. Survival advantage with imatinib compared to the combination interferon-a plus cytarabine in chronic phase CML: Historical comparison between two phase III trials. Blood 2006; 108: 1478-1484.
23. Kantarjian H, Talpaz M, O'Brien S, jones D, Giles F, Garcia-Manero D et al. Survival benefit with imatinib mesylate versus-interferon alfa-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood 2006; 108: 1835-1840.
24. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in 'good risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
25. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092.
26. Kantarjian H, Talpaz M, O'Brien S, Garcia M, Verstovsek S, Giles F et al. High dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-2878.
27. Baccarani M, Saglio G, Goldman JM, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia-net. Blood 2006; 108: 1809-1820.
28. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutations associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611-14614.
29. Shah NS, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel Abl kinase inhibitor. Science 2004; 305: 399-401.
30. Anand M, Khoramshad JS, Marin D, Apperley JF, Goldman JM, Kaeda JS. Varying response to escalating the dose of imatinib in CML patients who acquire a BCR-ABLM244V mutation. Blood 2006; 108: 2881-2882.
31. Khorashad J, Anand M, Marin D, Saunders S, Al-Jabary T, Iqbal A et al. The presence of a bcr-abl mutant allele in cml does not always explain clinical resistance to imatinib. Leukemia 2006; 20: 658-663.
32. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916.
33. Hatfield A, Owen S, Pilot PR. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007; 13: 13.
34. Atallah E, Kantarjian H, Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007; 13 14.
35. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.
36. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia-chromosome positive ALL. N Engl J Med 2006; 354: 2542-2551.
37. Hochhaus A, Kantarjian H, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303-2307.
38. Guo F, Rocha K, Bali P, Pranpat M, Fiscus W, Boyapalle S et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005; 65: 10536-10544.
39. Yokota A, Kimura S, Masuda S, Ashihara H, Ruroda J, Sato K et al. INNO-406, a novel Bcr-Abl/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo action. Blood 2007; 109: 306-314.
40. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006; 66: 11314-11322.
41. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with T315I BCR-ABL mutation. Blood 2007; 109: 500-502.
42. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y et al. Allosteric inhibittors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006; 2: 95-102.
43. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaedfa J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
44. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1421-1430.